Skip to content

Leucovorin Calcium

FDA-approved product (for solution, oral), marketed as Leucovorin Calcium, Leucovorin Calcium Preservative Free, Vykoura and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Leucovorin Calcium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Osteosarcoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Detoxifying agents for antineoplastic treatment
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli67.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae43.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis54.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Leucovorin Calcium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Combination Chemotherapy in Treating Children With Lymphoma

    NCT00002590 · start 1994-07

    Registered record
    Registry ID
    NCT00002590
    Conditions
    Lymphoma
    Interventions
    filgrastim; cyclophosphamide; cytarabine; daunorubicin hydrochloride; doxorubicin hydrochloride; etoposide; leucovorin calcium; methotrexate; pegaspargase; prednisone; thioguanine; vincristine sulfate; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1994-07
    Completion
    2007-03
    Enrolment
    221

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma
    Interventionfilgrastim; cyclophosphamide; cytarabine; daunorubicin hydrochloride +9 more
    PhasePhase 2
    Registry statusCompleted
  • Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia

    NCT00002494 · start 1992-05

    Registered record
    Registry ID
    NCT00002494
    Conditions
    Leukemia; Lymphoma
    Interventions
    cyclophosphamide; cytarabine; dexamethasone; doxorubicin hydrochloride; etoposide; ifosfamide; leucovorin calcium; mesna; methotrexate; prednisone; therapeutic hydrocortisone; vincristine sulfate; low-LET cobalt-60 gamma ray therapy; low-LET photon therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1992-05
    Completion
    2006-01
    Enrolment
    134

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia; Lymphoma
    Interventioncyclophosphamide; cytarabine; dexamethasone; doxorubicin hydrochloride +10 more
    PhasePhase 2
    Registry statusCompleted
  • Chemotherapy Via an Implantable Pump Compared With a Subcutaneous Port for Unresectable Liver Metastases in Patients With Resected Colorectal Cancer

    NCT00002793 · start 1991-01

    Registered record
    Registry ID
    NCT00002793
    Conditions
    Colorectal Cancer; Metastatic Cancer
    Interventions
    fluorouracil; leucovorin calcium
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    1991-01
    Completion
    Not recorded
    Enrolment
    336

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer; Metastatic Cancer
    Interventionfluorouracil; leucovorin calcium
    PhasePhase 3
    Registry statusUnknown
  • Fluorouracil and Leucovorin and/or Levamisole After Surgery In Treating Patients With Dukes' B Or Dukes' C Colon Cancer

    NCT00425152 · start 1989-07

    Registered record
    Registry ID
    NCT00425152
    Conditions
    Colorectal Cancer
    Interventions
    fluorouracil; leucovorin calcium; levamisole hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1989-07
    Completion
    2004-04
    Enrolment
    2,151

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer
    Interventionfluorouracil; leucovorin calcium; levamisole hydrochloride
    PhasePhase 3
    Registry statusCompleted
  • Comparison of Three Treatments for Pneumocystis Pneumonia in AIDS Patients

    NCT00000730

    Registered record
    Registry ID
    NCT00000730
    Conditions
    Pneumonia, Pneumocystis Carinii; HIV Infections
    Interventions
    Trimetrexate glucuronate; Methylprednisolone; Pentamidine isethionate; Sulfamethoxazole-Trimethoprim; Leucovorin calcium
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    Not recorded
    Completion
    1989-03
    Enrolment
    240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPneumonia, Pneumocystis Carinii; HIV Infections
    InterventionTrimetrexate glucuronate; Methylprednisolone; Pentamidine isethionate; Sulfamethoxazole-Trimethoprim +1 more
    PhasePhase 3
    Registry statusTerminated